Suppr超能文献

致心律失常性右室心肌病(ARVC)的射频消融治疗

Radiofrequency Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).

作者信息

Romero Jorge, Grushko Michael, Briceño David F, Natale Andrea, Di Biase Luigi

机构信息

Division of Cardiology at Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY, 10467, USA.

Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.

出版信息

Curr Cardiol Rep. 2017 Sep;19(9):82. doi: 10.1007/s11886-017-0893-3.

Abstract

PURPOSE OF REVIEW

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable form of cardiomyopathy, typically with autosomal dominant transmission, shown to be a defect in the cardiac desmosomes, with distinct regional and histopathological features. Clinically, this can ultimately result in bi-ventricular failure and/or malignant ventricular tachycardia (VT) via reentrant circuits created by patchy scar formation. We sought to review the current treatment for ventricular arrhythmias in the setting of ARVC, with particular attention to radiofrequency (RF) ablation and its varied techniques, along with potential therapies in the ablation spectrum.

RECENT FINDINGS

There is underwhelming data on the effectiveness of medical therapy for ARVC-related VT, including beta-blockers and antiarrhythmic medication. Primary and secondary prophylactic implantable-cardioverter defibrillator (ICD) implantation in higher-risk patients is recommended. More recently, RF ablation has been used for ARVC-related VT. Endocardial VT ablation in this setting can produce acute success, though recurrence rate is quite high, which may be explained by the more epicardial and patchy nature of the disease. Combined endocardial-epicardial ablation has since been shown to be feasible, safe, and with significantly better acute and long-term success, particularly when combined with scar dechanneling or homogenization of the scar. However, recurrence rates are not insignificant, and ablation does not eliminate the need for ICD placement. Medical therapy for ARVC-related VT is suboptimal. RF ablation techniques including endocardial and epicardial approaches appear to have the highest success rates for ARVC-related VT. Catheter ablation of VT in ARVC patients should be considered a potentially effective strategy for eliminating frequent VT episodes and ICD shocks rather than a curative therapeutic approach, until long-term efficacy has been consistently documented. Research into the optimal mapping and ablation techniques are promising and ongoing.

摘要

综述目的

致心律失常性右室心肌病(ARVC)是一种遗传性心肌病,通常呈常染色体显性遗传,其特征为心脏桥粒存在缺陷,具有独特的区域和组织病理学特点。临床上,这最终可通过片状瘢痕形成所产生的折返环路导致双心室衰竭和/或恶性室性心动过速(VT)。我们旨在综述ARVC背景下室性心律失常的当前治疗方法,尤其关注射频(RF)消融及其各种技术,以及消融领域的潜在治疗方法。

最新发现

关于ARVC相关VT的药物治疗有效性的数据并不充分,包括β受体阻滞剂和抗心律失常药物。建议对高危患者进行一级和二级预防性植入式心脏复律除颤器(ICD)植入。最近,RF消融已用于ARVC相关VT。在此背景下进行心内膜VT消融可取得急性成功,尽管复发率相当高,这可能是由于该疾病更具心外膜和片状的性质所致。此后已证明联合心内膜 - 心外膜消融是可行、安全的,并且急性和长期成功率显著更高,特别是在与瘢痕去通道化或瘢痕均质化联合使用时。然而,复发率仍然不低,并且消融并不能消除植入ICD的必要性。ARVC相关VT的药物治疗效果欠佳。包括心内膜和心外膜方法在内的RF消融技术似乎对ARVC相关VT具有最高的成功率。在ARVC患者中进行VT的导管消融应被视为消除频繁VT发作和减少ICD电击的一种潜在有效策略,而非一种治愈性治疗方法,除非长期疗效已得到一致证实。对最佳标测和消融技术的研究前景广阔且仍在进行中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验